BIB vs. IBID
BIB (ProShares Ultra Nasdaq Biotechnology) and IBID (iShares iBonds Oct 2027 Term TIPS ETF) are both exchange-traded funds - BIB is a Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%), while IBID is a Inflation-Protected Bonds fund tracking the ICE 2027 Maturity US Inflation-Linked Treasury Index. Both are passively managed. Over the past year, BIB returned 95.42% vs 4.04% for IBID. At a 0.04 correlation, their price movements are largely independent. BIB charges 0.95%/yr vs 0.10%/yr for IBID.
Performance
BIB vs. IBID - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BIB achieves a 10.33% return, which is significantly higher than IBID's 1.99% return.
BIB
- 1D
- 3.51%
- 1M
- 7.37%
- YTD
- 10.33%
- 6M
- 5.76%
- 1Y
- 95.42%
- 3Y*
- 18.87%
- 5Y*
- -0.66%
- 10Y*
- 9.50%
IBID
- 1D
- 0.00%
- 1M
- -0.19%
- YTD
- 1.99%
- 6M
- 2.08%
- 1Y
- 4.04%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
BIB vs. IBID - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 10.33% | 59.21% | -9.84% | 10.70% |
IBID iShares iBonds Oct 2027 Term TIPS ETF | 1.99% | 5.66% | 4.71% | 2.61% |
Correlation
The correlation between BIB and IBID is -0.15, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.15 |
Correlation (All Time) Calculated using the full available price history since Sep 15, 2023 | 0.04 |
The correlation between BIB and IBID shifts across timeframes, from -0.15 (1 year) to 0.04 (all time), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIB vs. IBID — Risk / Return Rank
BIB
IBID
BIB vs. IBID - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and iShares iBonds Oct 2027 Term TIPS ETF (IBID). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIB | IBID | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.91 | ||
| Sortino ratioReturn per unit of downside risk | -2.59 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.75 | -0.40 |
| Calmar ratioReturn relative to maximum drawdown | 5.67 | 8.22 | -2.55 |
| Martin ratioReturn relative to average drawdown | 17.31 | 30.99 | -13.68 |
Loading charts...
Drawdowns
BIB vs. IBID - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, which is greater than IBID's maximum drawdown of -1.28%. Use the drawdown chart below to compare losses from any high point for BIB and IBID.
Loading charts...
Drawdown Indicators
| BIB | IBID | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -1.28% | -65.96% |
Max Drawdown (1Y)Largest decline over 1 year | -16.92% | -0.49% | -16.43% |
Max Drawdown (3Y)Largest decline over 3 years | -45.30% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | — | — |
Current DrawdownCurrent decline from peak | -18.88% | -0.49% | -18.39% |
Average DrawdownAverage peak-to-trough decline | -32.71% | -0.22% | -32.49% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.53% | 0.13% | +5.40% |
Volatility
BIB vs. IBID - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 13.51% compared to iShares iBonds Oct 2027 Term TIPS ETF (IBID) at 0.35%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than IBID based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIB | IBID | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.51% | 0.35% | +13.16% |
Volatility (6M)Calculated over the trailing 6-month period | 31.64% | 0.86% | +30.78% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.47% | 1.23% | +39.24% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.60% | 2.24% | +41.36% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.50% | 2.24% | +44.26% |
BIB vs. IBID - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is higher than IBID's 0.10% expense ratio.
Dividends
BIB vs. IBID - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.56%, less than IBID's 3.68% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.56% | 0.77% | 1.69% | 0.07% | 0.03% |
IBID iShares iBonds Oct 2027 Term TIPS ETF | 3.68% | 4.43% | 4.24% | 0.81% | 0.00% |
Frequently Asked Questions
BIB and IBID have a correlation of -0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BIB has higher volatility (13.51%) compared to IBID (0.35%). In terms of maximum drawdown, BIB dropped -67.24% vs IBID's -1.28%.
On 1-year performance, BIB leads with 95.42% vs 4.04% for IBID. On fees, IBID is cheaper at 0.10% per year. On volatility, IBID has been the lower-risk option at 0.35%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 1-year period, BIB has performed better with a 95.42% return vs 4.04%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
IBID is cheaper with a 0.10% expense ratio, compared with 0.95% for BIB.
IBID has the higher dividend yield at 3.68%, compared with 0.56% for BIB.
BIB is categorized as Leveraged Equities, while IBID is Inflation-Protected Bonds. BIB tracks NASDAQ Biotechnology Index (200%), while IBID tracks ICE 2027 Maturity US Inflation-Linked Treasury Index. They also come from different issuers: ProShares and iShares. Their fees differ too: 0.95% for BIB and 0.10% for IBID.
IBID currently has the higher Sharpe Ratio (3.29 vs 2.38), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BIB and IBID
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer